Statin Therapy

Statins remain widely underused across most low- and middle-income countries, with about one in 10 eligible people using statins for primary prevention and about one in five eligible people using them for secondary prevention.

The benefits of statins in reducing cardiovascular disease and mortality “outweigh” the associated increased risk for type 2 diabetes in patients with rheumatoid arthritis, according to data published in Arthritis Care & Research.

Compared with white patients, Black patients had lower odds of receiving statins for secondary cardiovascular disease prevention after kidney transplant.

The U.S. Preventive Services Task Force recommended statins for the primary prevention of CVD in patients aged 40 to 75 years with at least one CVD risk factor and 10% or greater 10-year risk for CVD.

As many as 50% of patients prescribed statins take reduced or no doses due to perceived statin intolerance, but the actual prevalence of statin intolerance is less than 10%, according to a meta-analysis of more than 4 million patients.

Only 30% to 50% of U.S. adults achieved sustainable BP control over 18 months after BP-lowering drug initiation, according to results of an electronic health record-based longitudinal cohort study.

A medical team in Maryland successfully transplanted a genetically modified pig heart into a human for the first time in history.

In a new analysis of the REDUCE-IT trial, the treatment effect of icosapent ethyl was consistent across different agents and categories of statins patients were taking.

Vitamin D and thyroid hormones are important modulators in the treatment of cardiometabolic disease and should be incorporated into clinical decision making, according to a speaker.

Concordance of statin prescription between web-based app for consumer use and clinician assessment.